In a study that involved more than 31,000 women who are carriers of disease-associated mutations in the BRCA1 or BRCA2 genes, researchers identified mutations that were associated with significantly ...

Accuracy and Surgical Impact of Magnetic Resonance Imaging in Breast Cancer Staging: Systematic Review and Meta-Analysis in Detection of Multifocal and Multicentric Cancer Among the most promising ...

“Ovarian cancer (OC) is the third most prevalent type of gynecologic cancer affecting women after cervical and uterine cancer [1]. It is also considered the most fatal of all gynecological cancers [..

Three decades after discoveries linking mutations in the BRCA1 gene to breast and ovarian cancer susceptibility, research led by Mays Cancer Center at The University of Texas Health Science Center at ...

A new research paper was published in Oncotarget's Volume 15 on February 22, 2024, entitled, "Prevalence and spectrum of germline BRCA1 and BRCA2 in a cohort of ovarian cancer patients from the ...

A small percentage of ovarian cancers are hereditary, driven by inherited mutations in genes such as BRCA1 and BRCA2. Most ovarian cancers are “sporadic,” however, meaning they are driven by mutations ...

Germline pathogenic variants contribute to 15%-20% of ovarian cancer cases, with BRCA1/2 mutations accounting for 65%-85% of these cases. Disparities in genetic testing uptake exist across racial, ...

Ovarian cancer standard of care has not advanced in over 30 years, but a new DNA-based immunotherapy could be a gamechanger, showing major survival gains in clinical trials.

A U.K. lab has received a funding boost to develop the world’s first vaccine for ovarian cancer. Over 12,000 women in the U.S. die from ovarian cancer each year and the disease is often diagnosed at ...